News | August 14, 2008

Abbott, AstraZeneca Expand Relationship to Include Co-Promotion of CRESTOR

August 15, 2008 - Abbott and AstraZeneca said this week they entered into an agreement for Abbott to promote AstraZeneca’s CRESTOR (rosuvastatin calcium), a medication used along with diet to reduce high cholesterol.

Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote CRESTOR alongside AstraZeneca in the U.S., excluding Puerto Rico. Specific financial terms were not disclosed.

CRESTOR is a once-daily prescription statin medication indicated for use as an adjunct to diet in the treatment of various lipid disorders including primary hyperlipidemia, mixed dyslipidemia and isolated hypertriglyceridemia, and to slow the progression of atherosclerosis. CRESTOR is available in a 5, 10, 20, and 40 mg dose.

This agreement is the second collaboration between AstraZeneca and Abbott. In 2006, the companies announced an agreement to develop a fixed-dose combination of the active ingredients in Abbott's investigational TriLipix (fenofibric acid) and AstraZeneca’s CRESTOR, with plans to submit a New Drug Application (NDA) to the FDA in 2009. An NDA for TriLipix for use as monotherapy and in combination with statins has been submitted to the FDA and is currently under review.

For more information: www.crestor.com, www.abbott.com

Related Content

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Overlay Init